Open-label, long-term follow-up of safety and biochemical disease control of Infacort in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enrolled in the Infacort 003 study

Trial Profile

Open-label, long-term follow-up of safety and biochemical disease control of Infacort in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enrolled in the Infacort 003 study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Hydrocortisone (Primary)
  • Indications Adrenal insufficiency; Congenital adrenal hyperplasia
  • Focus Adverse reactions; Registrational
  • Acronyms Infacort004
  • Sponsors Diurnal
  • Most Recent Events

    • 07 Nov 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
    • 07 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 07 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top